CancerTherapyAdvisor· @CancerTherAdvsr · X·· 1 天前评分70
正文 · 原文
NATALEE: Adjuvant Ribociclib Plus NSAI Improves Long-Term Survival in HR+/HER2- Early Breast Cancer
Ribociclib plus NSAI therapy was associated with significant improvement in OS, at a rate of 91.9% at 6 years compared to 89.7% with NSAI alone #ESMO26
🔗 https://bit.ly/4jySLyB
92 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：CancerTherapyAdvisor · x.com